Nykode Therapeutics AS (OSL:NYKD)
kr 2.974 -0.046 (-1.52%) Market Cap: 971.15 Mil Enterprise Value: -397.26 Mil PE Ratio: 0 PB Ratio: 0.65 GF Score: 46/100

Nykode Therapeutics ASA at Jefferies London Healthcare Conference Transcript

Nov 17, 2022 / NTS GMT
Release Date Price: kr27.42 (-1.30%)
Unidentified Participant

Good afternoon, everyone. Thank you for coming. Happy to be here today with Nykode with Michael Engsig, the CEO; and Agnete Fredriksen, the CFO of the company, who will be going over their company presentation.

So I'll just hand over to Michael now. And then at the end, if we have time, we could do a brief Q&A. Thanks.

Michael Engsig
Nykode Therapeutics ASA - CEO

Thank you very much, [Carlos]. And well, welcome this afternoon here to the conference. Again, thanks for Jefferies for hosting us.

We'll just do a introduction to Nykode, run through the company, the technology, and the recent clinical data. I want to elaborate on that one. So just -- we assume you're all familiar with the forward-looking statements on that notice. We'll move forward.

I'm not alone here today. I'm happy to have with me Co-Founder and Chief Business Officer, Agnete Fredriksen, who will do the deep dive on the technology aspects. And I'm Michael, CEO of Nykode.

For those of you who are not familiar with Nykode, we are committed to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot